Cargando…

Implementation of Isavuconazole in a Fluorescence-Based High-Performance Liquid Chromatography Kit Allowing Simultaneous Detection of All Four Currently Licensed Mold-Active Triazoles

Isavuconazole (ISZ) is a newly available broad-spectrum triazole agent recently approved for the treatment of both invasive aspergillosis and mucormycosis. The aim of this study was to develop a simple and reliable method for therapeutic drug monitoring (TDM) of ISZ in human plasma samples. The meth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jørgensen, René, Andersen, Siri Rytcher, Astvad, Karen Marie Thyssen, Arendrup, Maiken Cavling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5425791/ https://www.ncbi.nlm.nih.gov/pubmed/28497121 http://dx.doi.org/10.1128/mSphere.00098-17

Ejemplares similares

EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates
por: Jørgensen, Karin Meinike, et al.
Publicado: (2019)

In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order
por: Arendrup, Maiken Cavling, et al.
Publicado: (2015)

A Pragmatic Approach to Susceptibility Classification of Yeasts without EUCAST Clinical Breakpoints
por: Astvad, Karen Marie Thyssen, et al.
Publicado: (2022)

Evaluation of MIC Strip Isavuconazole Test for Susceptibility Testing of Wild-Type and Non-Wild-Type Aspergillus fumigatus Isolates
por: Arendrup, Maiken Cavling, et al.
Publicado: (2016)

Increasing Terbinafine Resistance in Danish Trichophyton Isolates 2019–2020
por: Astvad, Karen Marie Thyssen, et al.
Publicado: (2022)

Correction: Astvad et al. Increasing Terbinafine Resistance in Danish Trichophyton Isolates 2019–2020. J. Fungi 2022, 8, 150
por: Astvad, Karen Marie Thyssen, et al.
Publicado: (2022)

Disinfection trials with terbinafine‐susceptible and terbinafine‐resistant dermatophytes
por: Skaastrup, Kristoffer Nagy, et al.
Publicado: (2022)

Spectrophotometric detection of azole-resistant Aspergillus fumigatus with the EUCAST broth microdilution method: is it time for automated MIC reading of EUCAST antifungal susceptibility testing of Aspergillus species?
por: Meletiadis, Joseph, et al.
Publicado: (2022)

Isavuconazole for COVID-19-Associated Invasive Mold Infections
por: Ullah, Nadir, et al.
Publicado: (2022)

EUCAST Ibrexafungerp MICs and Wild-Type Upper Limits for Contemporary Danish Yeast Isolates
por: Jørgensen, Karin M., et al.
Publicado: (2022)

Breaking the mold: A case of pulmonary mucormycosis treated with isavuconazole
por: Huggins, Jonathan, et al.
Publicado: (2018)

Invasive aspergillosis in patients with severe COVID-19 pneumonia
por: Helleberg, Marie, et al.
Publicado: (2021)

Dissection of the Activity of Agricultural Fungicides against Clinical Aspergillus Isolates with and without Environmentally and Medically Induced Azole Resistance
por: Jørgensen, Karin Meinike, et al.
Publicado: (2021)

Early phenotypic detection of fluconazole- and anidulafungin-resistant Candida glabrata isolates
por: Georgiou, Panagiota-Christina, et al.
Publicado: (2022)

Azole resistance in Aspergillus fumigatus. The first 2‐year's Data from the Danish National Surveillance Study, 2018–2020
por: Risum, Malene, et al.
Publicado: (2022)

Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK
por: Bagshaw, Emma, et al.
Publicado: (2018)

Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response
por: Kovanda, Laura L., et al.
Publicado: (2017)

Diagnostic Performance of T2Candida Among ICU Patients With Risk Factors for Invasive Candidiasis
por: Arendrup, Maiken Cavling, et al.
Publicado: (2019)

In vitro Activity of Isavuconazole and Comparators Against Clinical Isolates of Molds from a Multicenter Study in China
por: Jing, Ran, et al.
Publicado: (2022)

Pulmonary mucormycosis in the aftermath of critical COVID-19 in an immunocompromised patient: Mind the diagnostic gap
por: Crone, Cornelia Geisler, et al.
Publicado: (2022)

850. Real-world effectiveness and safety compared among isavuconazole, amphotericin B, and voriconazole in invasive mold disease patients
por: Qiu, Ye, et al.
Publicado: (2023)

In Vivo Selection of a Unique Tandem Repeat Mediated Azole Resistance Mechanism (TR(120)) in Aspergillus fumigatus cyp51A, Denmark
por: Hare, Rasmus K., et al.
Publicado: (2019)

868. In Vitro Activity of Isavuconazole and Other Mould-Active Triazoles Against Aspergillus fumigatus With and Without cyp51 Alterations
por: Pfaller, Michael A, et al.
Publicado: (2022)

Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications
por: Rogers, Thomas R, et al.
Publicado: (2022)

The fading boundaries between patient and environmental routes of triazole resistance selection in Aspergillus fumigatus
por: Buil, Jochem B., et al.
Publicado: (2019)

Population Pharmacokinetics and Pharmacodynamic Target Attainment of Isavuconazole against Aspergillus fumigatus and Aspergillus flavus in Adult Patients with Invasive Fungal Diseases: Should Therapeutic Drug Monitoring for Isavuconazole Be Considered as Mandatory as for the Other Mold-Active Azoles?
por: Cojutti, Pier Giorgio, et al.
Publicado: (2021)

Isavuconazole as salvage therapy for mucormycosis
por: Graves, Bianca, et al.
Publicado: (2016)

Posaconazole and isavuconazole induced hypomagnesaemia
por: Burston, John, et al.
Publicado: (2018)

Isavuconazole for invasive fungal infections
Publicado: (2020)

2110. Treatment of Coccidioidomycosis with Isavuconazole
por: Jamros, Christina, et al.
Publicado: (2019)

Isavuconazole Pharmacokinetics and Pharmacodynamics in Children
por: Elhence, Hirsh, et al.
Publicado: (2022)

Implementation of a Dual-Column Liquid Chromatography-Tandem Mass-Spectrometry Method for the Quantification of Isavuconazole in Clinical Practice
por: Enko, Dietmar, et al.
Publicado: (2021)

Adverse Events Associated with Universal versus Targeted Antifungal Prophylaxis among Lung Transplant Recipients—A Nationwide Cohort Study 2010–2019
por: Crone, Cornelia Geisler, et al.
Publicado: (2022)

Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses
por: Thompson, George R., et al.
Publicado: (2016)

393. Isavuconazole in the Treatment of Coccidioidal Meningitis
por: Heidari, Arash, et al.
Publicado: (2018)

Isavuconazole Kinetic Exploration for Clinical Practice
por: Darnaud, Léa, et al.
Publicado: (2018)

Rhinoorbital mucormycosis in the immunocompetent: Experience with Isavuconazole
por: Ilharco, Marta, et al.
Publicado: (2019)

Isavuconazole—Animal Data and Clinical Data
por: Pagano, Livio, et al.
Publicado: (2020)

1149. Baseline Chest CT Findings in Patients with Pulmonary Mold Infections: A Post-Hoc Analysis from the Phase 3 SECURE Study that Compared Isavuconazole to Voriconazole for the Primary Treatment of Invasive Mold Disease
por: Hamed, Kamal, et al.
Publicado: (2020)

Recurrent prosthetic valve endocarditis caused by Aspergillus delacroxii (formerly Aspergillus nidulans var. echinulatus)
por: Uhrin, Gábor Balázs, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_t9ln5u2vfegtbbq3sf479l2j1d